On August 17, AutoBio Diagnostics released its first-half results of 2022. The company achieved CNY 2.070 billion revenue by the end of June, with a year-on-year increase of 23.41%. The net profit attributable to shareholders was CNY 534 million, increasing 29.28% than the last year.

During the reporting period, the company has continuously strengthened investment in research and development, actively explored new fields and developed new products. The R&D investment achieved CNY 252.7126 million, accounting for 12.21% of total revenue, and some projects have achieved initial results.

As of June 30, 2022, the company has obtained 1,033 patents, including 50 international patents, 108 national invention patents, 795 patents for utility model and 80 industrial design patents. The company has obtained 617 NMPA certificates and obtained EU CE certification for 435 products. The company has successively undertaken 11 national projects, 18 provincial projects, 24 urban projects, and has fully participated in the formulation of 93 industry standards.

In April 2022, the company's new generation of high-throughput automatic chemiluminescence immunoassay analyzer AutoLumo A6000 series received NMPA certificate issued by the Henan Provincial Drug Administration. The certification of this series products further enriches the chemiluminescence product line, which can meet the detection needs of large and medium-sized medical laboratories. During the reporting period, the company launched a new self-developed automatic assembly line Autolas X-1 Series. The assembly line has improved a number of key performance indicators, it can better control costs and meet the needs of local laboratories in China.

About AutoBio

Autobio Diagnostics Co., Ltd was founded in 1998, headquartered in National Eco & Tech Zone, Zhengzhou.

Autobio specialized in R & D, production, marketing and service of clinical diagnostic products, especially covering immunoassay, microbiology and biochemistry fields. Meanwhile, Autobio is also actively planning the developments in the field of molecular diagnostics and provides a comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the main board in Shanghai,China. In 2019, Autobio’s revenue achieved USD412 millions, a year-on-year increase of 38.85%; in 2020, Autobio’s revenue achieved USD459 millions.